TRIAL RESULTS · SIDE EFFECTS
Triptorelin side effects
ANSWER
17 trials of Triptorelin posted side-effect results, none against placebo, so no placebo rate exists to compare. Most reported: hot flush, vaginal haemorrhage, upper respiratory tract infection. Read from ClinicalTrials.gov on 2026-10-03. Not medical advice.
Trial register
Trials with posted results
17
with an arm on Triptorelin, of 317 registered
Against placebo
0
placebo-controlled trials
People in those trials
0
on Triptorelin · 0 on placebo
Read
2026-10-03
ClinicalTrials.gov
ALL TRIALS
The 100 most reported of 327 side effects reported
Every trial with posted results and an arm on Triptorelin (n ≥ 20), all phases, by people affected. Placebo is shown where placebo-controlled trials reported the same event. Comparator arms are not counted.
| Side effect | Organ system | Triptorelin | Placebo | Trials |
|---|---|---|---|---|
| Hot flush | Vascular disorders | 34.1% (514 of 1,509) | - | 11 |
| Vaginal haemorrhage | Reproductive system and breast disorders | 40.7% (136 of 334) | - | 2 |
| Upper respiratory tract infection | Infections and infestations | 12.7% (91 of 719) | - | 4 |
| Hypertension | Vascular disorders | 7.0% (68 of 965) | - | 9 |
| Arthralgia | Musculoskeletal and connective tissue disorders | 7.0% (63 of 899) | - | 7 |
| Nasopharyngitis | Infections and infestations | 8.3% (60 of 725) | - | 4 |
| Hyperhidrosis | Skin and subcutaneous tissue disorders | 6.2% (51 of 828) | - | 5 |
| Insomnia | General disorders | 6.2% (41 of 659) | - | 7 |
| Back pain | Musculoskeletal and connective tissue disorders | 7.4% (40 of 539) | - | 3 |
| Headache | Nervous system disorders | 5.5% (39 of 710) | - | 6 |
| hot flashes/flushes | Endocrine disorders | 71.4% (35 of 49) | - | 1 |
| Night sweats | Skin and subcutaneous tissue disorders | 10.7% (32 of 299) | - | 1 |
| Urinary tract infection | Renal and urinary disorders | 6.7% (30 of 448) | - | 4 |
| Cough | Respiratory, thoracic and mediastinal disorders | 5.2% (28 of 535) | - | 6 |
| Pyrexia | General disorders | 4.5% (27 of 599) | - | 3 |
| Nausea | Gastrointestinal disorders | 12.8% (25 of 195) | - | 3 |
| Fatigue | General disorders | 4.0% (23 of 579) | - | 7 |
| Erectile dysfunction | Reproductive system and breast disorders | 6.7% (23 of 345) | - | 3 |
| Anaemia | Blood and lymphatic system disorders | 2.1% (21 of 1,016) | - | 6 |
| Pain in extremity | Musculoskeletal and connective tissue disorders | 4.0% (21 of 524) | - | 3 |
| Influenza | Infections and infestations | 5.7% (20 of 351) | - | 3 |
| Mood alteration | Nervous system disorders | 38.8% (19 of 49) | - | 1 |
| Abdominal pain lower | Gastrointestinal disorders | 4.5% (18 of 404) | - | 2 |
| Hair loss/alopecia (scalp or body) | Skin and subcutaneous tissue disorders | 36.7% (18 of 49) | - | 1 |
| Hot Flashes/Flushes | Vascular disorders | 69.2% (18 of 26) | - | 1 |
| Constipation | Gastrointestinal disorders | 6.2% (17 of 274) | - | 3 |
| Glucose, serum-high (hyperglycemia) | Metabolism and nutrition disorders | 34.7% (17 of 49) | - | 1 |
| Pain | General disorders | 34.7% (17 of 49) | - | 1 |
| Protein urine present | Investigations | 5.7% (17 of 299) | - | 1 |
| Menorrhagia | Reproductive system and breast disorders | 5.7% (17 of 299) | - | 1 |
| Dizziness | Nervous system disorders | 2.7% (16 of 599) | - | 3 |
| Vaginal infection | Infections and infestations | 5.0% (15 of 299) | - | 1 |
| Abdominal pain | Gastrointestinal disorders | 2.6% (14 of 541) | - | 5 |
| Vomiting | Gastrointestinal disorders | 4.6% (14 of 307) | - | 4 |
| Abdominal pain upper | Gastrointestinal disorders | 4.7% (14 of 299) | - | 1 |
| Fall | Injury, poisoning and procedural complications | 2.2% (13 of 596) | - | 3 |
| Diarrhoea | Gastrointestinal disorders | 2.1% (13 of 624) | - | 2 |
| Alanine aminotransferase increased | Investigations | 4.3% (13 of 300) | - | 2 |
| Hot Flush | Vascular disorders | 10.3% (13 of 126) | - | 1 |
| Aspartate aminotransferase increased | Investigations | 4.0% (12 of 300) | - | 2 |
| Weight Increased | Investigations | 9.5% (12 of 126) | - | 1 |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | 4.0% (12 of 299) | - | 1 |
| ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | 22.4% (11 of 49) | - | 1 |
| Headaches | General disorders | 22.4% (11 of 49) | - | 1 |
| Lethargy | General disorders | 9.2% (11 of 120) | - | 1 |
| Bronchitis | Infections and infestations | 1.1% (10 of 899) | - | 6 |
| Myalgia | Musculoskeletal and connective tissue disorders | 5.0% (9 of 181) | - | 3 |
| Sweating (diaphoresis) | General disorders | 18.4% (9 of 49) | - | 1 |
| Testicular atrophy | Reproductive system and breast disorders | 7.5% (9 of 120) | - | 1 |
| Oedema peripheral | General disorders | 3.2% (8 of 250) | - | 3 |
| Urinary retention | Renal and urinary disorders | 1.5% (8 of 548) | - | 3 |
| Infection with unknown ANC | Infections and infestations | 16.3% (8 of 49) | - | 1 |
| Weight Decreased | Investigations | 5.6% (7 of 126) | - | 1 |
| Injection site pain | General disorders | 8.3% (6 of 72) | - | 2 |
| AST, SGOT (serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | 12.2% (6 of 49) | - | 1 |
| Metabolic/Laboratory - Other | Metabolism and nutrition disorders | 12.2% (6 of 49) | - | 1 |
| Neck pain | Musculoskeletal and connective tissue disorders | 5.0% (6 of 120) | - | 1 |
| Pneumonia | Infections and infestations | 1.0% (5 of 496) | - | 4 |
| Nocturia | Renal and urinary disorders | 1.5% (5 of 334) | - | 3 |
| Weight gain | General disorders | 1.3% (5 of 374) | - | 2 |
| Antepartum haemorrhage | Pregnancy, puerperium and perinatal conditions | 4.2% (5 of 120) | - | 1 |
| Myocardial infarction | Cardiac disorders | 0.6% (4 of 691) | - | 4 |
| Atrial fibrillation | Cardiac disorders | 0.9% (4 of 445) | - | 2 |
| Sleep disorder | Psychiatric disorders | 1.9% (4 of 208) | - | 2 |
| Dermatology/Skin - Other | Skin and subcutaneous tissue disorders | 8.2% (4 of 49) | - | 1 |
| Distension/bloating, abdominal | Gastrointestinal disorders | 8.2% (4 of 49) | - | 1 |
| Heartburn/dyspepsia | Gastrointestinal disorders | 8.2% (4 of 49) | - | 1 |
| Infection - Other | Infections and infestations | 8.2% (4 of 49) | - | 1 |
| Potassium, serum-low (hypokalemia) | Metabolism and nutrition disorders | 8.2% (4 of 49) | - | 1 |
| Neuropathy: sensory | Nervous system disorders | 8.2% (4 of 49) | - | 1 |
| Pain - Other | General disorders | 8.2% (4 of 49) | - | 1 |
| COVID-19 | Infections and infestations | 2.8% (4 of 145) | - | 1 |
| Foot fracture | Injury, poisoning and procedural complications | 1.4% (3 of 217) | - | 3 |
| Acute myocardial infarction | Cardiac disorders | 0.8% (3 of 385) | - | 3 |
| Depression | Psychiatric disorders | 0.6% (3 of 471) | - | 3 |
| Haematuria | Renal and urinary disorders | 0.9% (3 of 349) | - | 3 |
| Asthenia | General disorders | 0.5% (3 of 556) | - | 3 |
| Alopecia | Skin and subcutaneous tissue disorders | 2.3% (3 of 130) | - | 2 |
| Herpes zoster | Infections and infestations | 2.3% (3 of 130) | - | 2 |
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1.3% (3 of 240) | - | 2 |
| Renal failure | Renal and urinary disorders | 0.7% (3 of 428) | - | 2 |
| Urosepsis | Infections and infestations | 0.7% (3 of 428) | - | 2 |
| Hyperglycaemia | Endocrine disorders | 1.2% (3 of 246) | - | 2 |
| Mucositis/stomatitis (clinical exam) | Gastrointestinal disorders | 6.1% (3 of 49) | - | 1 |
| Edema - limb | Blood and lymphatic system disorders | 6.1% (3 of 49) | - | 1 |
| Vaginal dryness | Reproductive system and breast disorders | 6.1% (3 of 49) | - | 1 |
| Erectile Dysfunction | Reproductive system and breast disorders | 2.4% (3 of 126) | - | 1 |
| Inguinal hernia | Gastrointestinal disorders | 0.6% (2 of 353) | - | 3 |
| Leukopenia | Blood and lymphatic system disorders | 1.5% (2 of 130) | - | 2 |
| Cellulitis | Infections and infestations | 1.6% (2 of 128) | - | 2 |
| Chest pain | General disorders | 1.5% (2 of 130) | - | 2 |
| Angina pectoris | Cardiac disorders | 0.9% (2 of 223) | - | 2 |
| Hip fracture | Injury, poisoning and procedural complications | 0.4% (2 of 445) | - | 2 |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | 0.9% (2 of 229) | - | 2 |
| Inguinal hernia, obstructive | Gastrointestinal disorders | 1.0% (2 of 208) | - | 2 |
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1.0% (2 of 208) | - | 2 |
| Sepsis | Infections and infestations | 0.5% (2 of 402) | - | 2 |
| Urethral stenosis | Renal and urinary disorders | 1.0% (2 of 208) | - | 2 |
| Death | General disorders | 0.8% (2 of 265) | - | 2 |
| Alkaline phosphatase | Metabolism and nutrition disorders | 4.1% (2 of 49) | - | 1 |
Source: ClinicalTrials.gov posted results, read 2026-10-03. A trial lists events above its own reporting threshold, so a rare event may be missing from some trials. Not medical advice.
REGISTERED STUDIES
317 registered clinical trials of Triptorelin
The 10 most recently updated are listed.
| 2022-501024-20-00 | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence Status: UNKNOWN · Updated 2026-09-29 |
|---|---|
| 2024-519655-28-00 | OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women Status: UNKNOWN · Updated 2026-09-14 |
| NCT07816562 | Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) Status: RECRUITING · Updated 2026-09-11 |
| 2023-509494-23-00 | DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERMEDIATE UNFAVORABLE RISK PROSTATE CANCER Status: UNKNOWN · Updated 2026-09-07 |
| NCT06763926 | Intranasal Nafarelin For Triggering Oocyte Maturation Status: NOT_YET_RECRUITING · Updated 2026-09-03 |
| NCT02005887 | TRial on the Endocrine Activity of Neoadjuvant Degarelix Status: COMPLETED · Updated 2026-09-02 |
| NCT06513962 | Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer Status: RECRUITING · Updated 2026-08-31 |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer Status: ACTIVE_NOT_RECRUITING · Updated 2026-08-28 |
| NCT00066690 | Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Status: COMPLETED · Updated 2026-08-26 |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Status: NOT_YET_RECRUITING · Updated 2026-08-26 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.